Cipla Propels 'Lung Leadership' Plans
Reimagines Operating Models As Q4 Sales Hit By COVID-19
Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.
